Vgenomics & Meril Genomics Collaborate to Expand Genomic Diagnostics in India

The partnership combines Vgenomics' bioinformatics capabilities, AI-driven research, and translational genomics with Meril Genomics’ strengths in diagnostics and molecular biology.

Vgenomics, a precision health company, and Meril Genomics, a diagnostics and molecular biology provider, have announced a collaboration to strengthen the delivery of advanced genomic diagnostics to hospitals and research centres across India.

The partnership combines Vgenomics' bioinformatics capabilities, AI-driven research, and translational genomics with Meril Genomics’ strengths in diagnostics and molecular biology.

The alliance focuses on increasing access to precision medicine through three key diagnostic tools—Non-Invasive Prenatal Testing (NIPT), targeted Next-Generation Sequencing (tNGS) for Tuberculosis (TB), and Whole Exome Sequencing (WES) for rare disease diagnosis.

Focus on Maternal, Infectious, and Genetic Conditions

The introduction of NIPT under the collaboration is targeted at early screening of chromosomal abnormalities such as Down syndrome. The service is particularly aimed at supporting pregnancies among women of advanced maternal age, offering a non-invasive method to detect risks early and contribute to improved neonatal outcomes.

In response to the country’s high tuberculosis burden, with India accounting for approximately 26 per cent of global TB cases annually, the partnership will introduce targeted Next-Generation Sequencing. The goal is to enhance the accuracy and speed of TB diagnosis, thereby supporting more timely and effective treatment.

The initiative also includes the implementation of Whole Exome Sequencing to address the diagnostic challenges faced by individuals with rare genetic disorders. With an estimated 70 million people in India affected by such conditions, integrating WES with AI-driven analytics is expected to reduce prolonged diagnostic delays and enable more precise clinical decision-making.